{"id":7909,"date":"2024-12-18T18:51:47","date_gmt":"2024-12-18T10:51:47","guid":{"rendered":"https:\/\/regask.com\/?p=7909"},"modified":"2024-12-18T18:51:47","modified_gmt":"2024-12-18T10:51:47","slug":"%e3%83%91%e3%83%a9%e3%82%b0%e3%82%a2%e3%82%a4-%e3%83%87%e3%82%a3%e3%83%8a%e3%83%93%e3%82%b5%e5%8c%bb%e8%96%ac%e5%93%81%e6%89%bf%e8%aa%8d%e3%82%ac%e3%82%a4%e3%83%89%e3%83%a9%e3%82%a4%e3%83%b3","status":"publish","type":"post","link":"https:\/\/regask.com\/ja\/paraguay-dinavisa-drug-approval-guideline\/","title":{"rendered":"DINAVISA (\u30d1\u30e9\u30b0\u30a2\u30a4) \u304c\u512a\u826f\u8f38\u51fa\u5165\u306b\u95a2\u3059\u308b\u65b0\u3057\u3044\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u3092\u627f\u8a8d"},"content":{"rendered":"<p>2024\u5e7412\u67082\u65e5\u3001 <a href=\"https:\/\/regask.com\/ja\/%e3%83%91%e3%83%a9%e3%82%b0%e3%82%a2%e3%82%a4%e3%81%ae%e4%b9%b3%e7%b3%96%e4%b8%8d%e4%bd%bf%e7%94%a8%e9%a3%9f%e5%93%81%e8%a6%8f%e5%88%b6\/\">\u56fd\u5bb6\u885b\u751f\u76e3\u8996\u5c40<\/a> \uff08DINAVISA\uff09\u306f\u3001 <strong>\u300c\u533b\u85ac\u54c1\u306e\u767b\u9332\u306e\u305f\u3081\u306e\u9069\u6b63\u8a55\u4fa1\u57fa\u6e96\u30ac\u30a4\u30c9\u300d<\/strong> \u3053\u306e\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u306f\u3001\u898f\u5236\u67a0\u7d44\u307f\u306e\u5927\u5e45\u306a\u66f4\u65b0\u3067\u3042\u308a\u3001\u660e\u78ba\u3067\u900f\u660e\u306a\u8a55\u4fa1\u30d7\u30ed\u30bb\u30b9\u3092\u901a\u3058\u3066\u533b\u85ac\u54c1\u306e\u54c1\u8cea\u3001\u5b89\u5168\u6027\u3001\u6709\u52b9\u6027\u3092\u78ba\u4fdd\u3059\u308b\u3053\u3068\u306b\u91cd\u70b9\u3092\u7f6e\u3044\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>\u3053\u306e\u30ac\u30a4\u30c9\u306f\u3001DINAVISA \u306e\u624b\u9806\u3092\u56fd\u969b\u57fa\u6e96\u306b\u5408\u308f\u305b\u3001\u4e16\u754c\u306e\u898f\u5236\u57fa\u6e96\u3068\u306e\u8abf\u548c\u3092\u4fc3\u9032\u3059\u308b\u3053\u3068\u3092\u76ee\u7684\u3068\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u30ac\u30a4\u30c9\u306f\u3001\u533b\u85ac\u54c1\u3001\u751f\u7269\u88fd\u5264\u3001\u5316\u5b66\u85ac\u54c1\u3001\u8a66\u85ac\u3001\u533b\u7642\u6a5f\u5668\u3001\u5316\u7ca7\u54c1\u307e\u305f\u306f\u6d88\u6bd2\u5264\u306b\u5206\u985e\u3055\u308c\u308b\u500b\u4eba\u885b\u751f\u7528\u54c1\u306a\u3069\u3001\u4eba\u4f53\u3078\u306e\u4f7f\u7528\u3092\u76ee\u7684\u3068\u3057\u305f\u3059\u3079\u3066\u306e\u533b\u85ac\u54c1\u306b\u9069\u7528\u3055\u308c\u307e\u3059\u3002<\/p>\n<p>\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u306e\u4e3b\u306a\u30cf\u30a4\u30e9\u30a4\u30c8\u306f\u6b21\u306e\u3068\u304a\u308a\u3067\u3059\u3002<\/p>\n<ul>\n<li>\u9075\u5b88 <strong>\u56fd\u969b\u57fa\u6e96<\/strong> \u533b\u85ac\u54c1\u8a55\u4fa1\u306e\u30d9\u30b9\u30c8\u30d7\u30e9\u30af\u30c6\u30a3\u30b9\u3002<\/li>\n<li>\u524d\u81e8\u5e8a\u8a66\u9a13\u3001\u81e8\u5e8a\u8a66\u9a13\u306e\u627f\u8a8d\u3001\u5e02\u8ca9\u5f8c\u306e\u5909\u66f4\u3001\u518d\u767b\u9332\u30d7\u30ed\u30bb\u30b9\u306a\u3069\u3001\u88fd\u54c1\u958b\u767a\u306e\u3042\u3089\u3086\u308b\u6bb5\u968e\u306b\u304a\u3051\u308b\u8a73\u7d30\u306a\u30b3\u30f3\u30d7\u30e9\u30a4\u30a2\u30f3\u30b9\u8981\u4ef6\u3002<\/li>\n<li>\u5f37\u8abf\u3059\u308b <strong>\u591a\u5206\u91ce\u306b\u308f\u305f\u308b\u30a2\u30d7\u30ed\u30fc\u30c1<\/strong> \u975e\u81e8\u5e8a\u3001\u81e8\u5e8a\u3001\u751f\u4f53\u9069\u5408\u6027\u3001\u88fd\u9020\u30d7\u30ed\u30bb\u30b9\u3001\u30ea\u30b9\u30af\u7ba1\u7406\u306e\u8a55\u4fa1\u3092\u7d71\u5408\u3057\u307e\u3059\u3002<\/li>\n<li>\u8a8d\u5b9a\u3055\u308c\u305f\u5c02\u9580\u5bb6\u306b\u3088\u308b\u8a55\u4fa1\u3092\u6d3b\u7528\u3059\u308b\u4ed5\u7d44\u307f <strong>\u56fd\u969b\u898f\u5236\u5f53\u5c40<\/strong> \u53b3\u683c\u306a\u5b89\u5168\u6027\u3068\u6709\u52b9\u6027\u306e\u57fa\u6e96\u3092\u7dad\u6301\u3057\u306a\u304c\u3089\u5be9\u67fb\u3092\u8fc5\u901f\u5316\u3057\u307e\u3059\u3002<\/li>\n<li>\u80b2\u6210\u306b\u91cd\u70b9\u3092\u7f6e\u304f <strong>\u7d99\u7d9a\u7684\u306a\u5c02\u9580\u80fd\u529b\u958b\u767a<\/strong> \u8a55\u4fa1\u8005\u9593\u306e\u6279\u5224\u7684\u601d\u8003\u3092\u4fc3\u9032\u3057\u3001\u6700\u65b0\u306e\u79d1\u5b66\u7684\u7406\u89e3\u306b\u57fa\u3065\u3044\u305f\u8a3c\u62e0\u306b\u57fa\u3065\u304f\u6c7a\u5b9a\u3092\u78ba\u5b9f\u306b\u4e0b\u305b\u308b\u3088\u3046\u306b\u3057\u307e\u3059\u3002<\/li>\n<\/ul>\n<p>\u65b0\u3057\u3044\u30ac\u30a4\u30c9\u306f\u3001\u533b\u85ac\u54c1\u306e\u8ca9\u58f2\u627f\u8a8d\u30d7\u30ed\u30bb\u30b9\u3092\u8fd1\u4ee3\u5316\u304a\u3088\u3073\u5408\u7406\u5316\u3057\u3001\u898f\u5236\u4e0a\u306e\u6c7a\u5b9a\u304c\u4e00\u8cab\u6027\u3068\u900f\u660e\u6027\u3092\u4fdd\u3061\u3001\u4e16\u754c\u7684\u306a\u6163\u884c\u306b\u6cbf\u3063\u305f\u3082\u306e\u3068\u306a\u308b\u3088\u3046\u4fdd\u8a3c\u3059\u308b\u305f\u3081\u306e\u91cd\u8981\u306a\u4e00\u6b69\u3067\u3059\u3002<\/p>\n<p>\u8a73\u7d30\u3084\u304a\u554f\u3044\u5408\u308f\u305b\u306b\u3064\u304d\u307e\u3057\u3066\u306f\u3001\u5f0a\u793e\u307e\u3067\u3054\u9023\u7d61\u304f\u3060\u3055\u3044\u3002<\/p>","protected":false},"excerpt":{"rendered":"<p>2024\u5e7412\u67082\u65e5\u3001\u56fd\u5bb6\u885b\u751f\u76e3\u7763\u5c40\uff08DINAVISA\uff09\u306f\u300c\u533b\u85ac\u54c1\u767b\u9332\u306e\u305f\u3081\u306e\u512a\u826f\u8a55\u4fa1\u5b9f\u52d9\u30ac\u30a4\u30c9\u300d\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u3053\u306e\u30ac\u30a4\u30c9\u306f\u3001\u898f\u5236\u67a0\u7d44\u307f\u306e\u5927\u5e45\u306a\u6539\u8a02\u3067\u3042\u308a\u3001\u660e\u78ba\u304b\u3064\u900f\u660e\u6027\u306e\u9ad8\u3044\u8a55\u4fa1\u30d7\u30ed\u30bb\u30b9\u3092\u901a\u3058\u3066\u533b\u85ac\u54c1\u306e\u54c1\u8cea\u3001\u5b89\u5168\u6027\u3001\u6709\u52b9\u6027\u3092\u78ba\u4fdd\u3059\u308b\u3053\u3068\u306b\u91cd\u70b9\u3092\u7f6e\u3044\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u30ac\u30a4\u30c9\u306f\u3001DINAVISA\u306e\u624b\u7d9a\u304d\u3092\u56fd\u969b\u57fa\u6e96\u306b\u5408\u308f\u305b\u3001\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u898f\u5236\u898f\u7bc4\u3068\u306e\u8abf\u548c\u3092\u4fc3\u9032\u3059\u308b\u3053\u3068\u3092\u76ee\u7684\u3068\u3057\u3066\u3044\u307e\u3059\u3002\u5bfe\u8c61\u3068\u306a\u308b\u306e\u306f\u3001\u533b\u85ac\u54c1\u3001\u751f\u7269\u88fd\u5264\u3001\u5316\u5b66\u85ac\u54c1\u3001\u8a66\u85ac\u3001\u533b\u7642\u6a5f\u5668\u3001\u5316\u7ca7\u54c1\u307e\u305f\u306f\u6d88\u6bd2\u5264\u306b\u5206\u985e\u3055\u308c\u308b\u30d1\u30fc\u30bd\u30ca\u30eb\u30b1\u30a2\u88fd\u54c1\u306a\u3069\u3001\u30d2\u30c8\u306b\u4f7f\u7528\u3055\u308c\u308b\u3059\u3079\u3066\u306e\u533b\u85ac\u54c1\u3067\u3059\u3002\u3053\u306e\u30ac\u30a4\u30c9\u306e\u4e3b\u306a\u30dd\u30a4\u30f3\u30c8\u306f\u4ee5\u4e0b\u306e\u3068\u304a\u308a\u3067\u3059\u3002\u533b\u85ac\u54c1\u8a55\u4fa1\u306b\u95a2\u3059\u308b\u56fd\u969b\u57fa\u6e96\u304a\u3088\u3073\u30d9\u30b9\u30c8\u30d7\u30e9\u30af\u30c6\u30a3\u30b9\u306e\u9075\u5b88\u3002\u8a73\u7d30\u2026<\/p>","protected":false},"author":43,"featured_media":7926,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[35,566],"tags":[496,609],"class_list":["post-7909","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-biotech-latest-insights","category-paraguay-regulation","tag-market-authorization-regs","tag-guideline"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Paraguay Issues New Guideline for Drug Approvals | RegASK<\/title>\n<meta name=\"description\" content=\"Paraguay\u2019s DINAVISA releases a new guideline for drug approvals, aligning with global standards for safety and efficacy. Read more at RegASK\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/ja\/\u30d1\u30e9\u30b0\u30a2\u30a4-\u30c7\u30a3\u30ca\u30d3\u30b5\u533b\u85ac\u54c1\u627f\u8a8d\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DINAVISA (Paraguay) Approves New Guideline for Good Evaluation Practices for Marketing Authorization\" \/>\n<meta property=\"og:description\" content=\"Paraguay\u2019s DINAVISA releases a new guideline for drug approvals, aligning with global standards for safety and efficacy. Read more at RegASK\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/ja\/\u30d1\u30e9\u30b0\u30a2\u30a4-\u30c7\u30a3\u30ca\u30d3\u30b5\u533b\u85ac\u54c1\u627f\u8a8d\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-18T10:51:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Reva Ananda\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Reva Ananda\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/\"},\"author\":{\"name\":\"Reva Ananda\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\"},\"headline\":\"DINAVISA (Paraguay) Approves New Guideline for Good Eva&hellip;\",\"datePublished\":\"2024-12-18T10:51:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/\"},\"wordCount\":232,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png\",\"keywords\":[\"Market authorization regs\",\"Guideline\"],\"articleSection\":[\"Pharma and Biotech\",\"Paraguay\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/\",\"name\":\"Paraguay Issues New Guideline for Drug Approvals | RegASK\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png\",\"datePublished\":\"2024-12-18T10:51:47+00:00\",\"description\":\"Paraguay\u2019s DINAVISA releases a new guideline for drug approvals, aligning with global standards for safety and efficacy. Read more at RegASK\",\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png\",\"width\":800,\"height\":600,\"caption\":\"Dinavisa Paraguay Approves New Guideline Good Evaluation Practices Marketing Authorization\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\",\"name\":\"RegASK\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"width\":401,\"height\":401,\"caption\":\"RegASK\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RegASKRegulatoryAffairs\\\/\",\"https:\\\/\\\/x.com\\\/ASKRegASK\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/RegASK\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@RegASK\",\"https:\\\/\\\/www.crunchbase.com\\\/organization\\\/regask\",\"https:\\\/\\\/www.bloomberg.com\\\/profile\\\/company\\\/1691237D:SP\",\"https:\\\/\\\/pitchbook.com\\\/profiles\\\/company\\\/265004-02\",\"https:\\\/\\\/www.cbinsights.com\\\/company\\\/RegASK\",\"https:\\\/\\\/vimeo.com\\\/RegASK\"],\"legalName\":\"RegASK PTE. LTD.\",\"foundingDate\":\"2018\",\"slogan\":\"Empowering Smarter Regulatory Decisions\",\"description\":\"Agentic AI regulatory intelligence and workflow orchestration platform for Life Sciences and Consumer Products. RegASK combines vertical LLMs, multi-agent AI architecture, and a global community of 1,800+ subject matter experts to deliver regulatory horizon scanning, impact analysis, compliance workflow automation, and audit-ready outputs across 160+ countries.\",\"areaServed\":\"Worldwide\",\"founder\":{\"@type\":\"Person\",\"name\":\"Caroline Shleifer\",\"jobTitle\":\"Founder & CEO\"},\"address\":{\"@type\":\"PostalAddress\",\"streetAddress\":\"79 Science Park Drive, #06-01, Cintech IV\",\"addressLocality\":\"Singapore\",\"postalCode\":\"118264\",\"addressCountry\":\"SG\"},\"contactPoint\":{\"@type\":\"ContactPoint\",\"telephone\":\"+65 6817 6290\",\"contactType\":\"customer service\",\"availableLanguage\":[\"English\",\"French\",\"Japanese\",\"Spanish\",\"Chinese\",\"German\"]},\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":50,\"maxValue\":100},\"knowsAbout\":[\"Regulatory Intelligence\",\"Regulatory Compliance\",\"Regulatory Affairs\",\"Workflow Orchestration\",\"Life Sciences Regulation\",\"Consumer Products Regulation\",\"AI-Driven Compliance\"],\"hasCertification\":[{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 42001:2023\"},{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 27001:2022\"},{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 27701\"},{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 27018:2019\"},{\"@type\":\"Certification\",\"name\":\"SOC 2 Type II\"}]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\",\"name\":\"Reva Ananda\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\u30d1\u30e9\u30b0\u30a2\u30a4\u3001\u533b\u85ac\u54c1\u627f\u8a8d\u306b\u95a2\u3059\u308b\u65b0\u305f\u306a\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u3092\u767a\u884c | RegASK","description":"\u30d1\u30e9\u30b0\u30a2\u30a4\u306eDINAVISA\u306f\u3001\u5b89\u5168\u6027\u3068\u6709\u52b9\u6027\u306b\u95a2\u3059\u308b\u4e16\u754c\u57fa\u6e96\u306b\u6cbf\u3063\u305f\u533b\u85ac\u54c1\u627f\u8a8d\u306e\u65b0\u3057\u3044\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u8a73\u7d30\u306fRegASK\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/ja\/\u30d1\u30e9\u30b0\u30a2\u30a4-\u30c7\u30a3\u30ca\u30d3\u30b5\u533b\u85ac\u54c1\u627f\u8a8d\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\/","og_locale":"ja_JP","og_type":"article","og_title":"DINAVISA (Paraguay) Approves New Guideline for Good Evaluation Practices for Marketing Authorization","og_description":"Paraguay\u2019s DINAVISA releases a new guideline for drug approvals, aligning with global standards for safety and efficacy. Read more at RegASK","og_url":"https:\/\/regask.com\/ja\/\u30d1\u30e9\u30b0\u30a2\u30a4-\u30c7\u30a3\u30ca\u30d3\u30b5\u533b\u85ac\u54c1\u627f\u8a8d\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2024-12-18T10:51:47+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png","type":"image\/png"}],"author":"Reva Ananda","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"\u57f7\u7b46\u8005":"Reva Ananda","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/#article","isPartOf":{"@id":"https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/"},"author":{"name":"Reva Ananda","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926"},"headline":"DINAVISA (Paraguay) Approves New Guideline for Good Eva&hellip;","datePublished":"2024-12-18T10:51:47+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/"},"wordCount":232,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png","keywords":["Market authorization regs","Guideline"],"articleSection":["Pharma and Biotech","Paraguay"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/","url":"https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/","name":"\u30d1\u30e9\u30b0\u30a2\u30a4\u3001\u533b\u85ac\u54c1\u627f\u8a8d\u306b\u95a2\u3059\u308b\u65b0\u305f\u306a\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u3092\u767a\u884c | RegASK","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png","datePublished":"2024-12-18T10:51:47+00:00","description":"\u30d1\u30e9\u30b0\u30a2\u30a4\u306eDINAVISA\u306f\u3001\u5b89\u5168\u6027\u3068\u6709\u52b9\u6027\u306b\u95a2\u3059\u308b\u4e16\u754c\u57fa\u6e96\u306b\u6cbf\u3063\u305f\u533b\u85ac\u54c1\u627f\u8a8d\u306e\u65b0\u3057\u3044\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u8a73\u7d30\u306fRegASK\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002","inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png","width":800,"height":600,"caption":"Dinavisa Paraguay Approves New Guideline Good Evaluation Practices Marketing Authorization"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"\u9ad8\u6027\u80fd\u30c1\u30fc\u30e0\u306e\u305f\u3081\u306e\u898f\u5236AI\u30aa\u30da\u30ec\u30fc\u30c6\u30a3\u30f3\u30b0\u30b7\u30b9\u30c6\u30e0","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/regask.com\/#organization","name":"RegASK","url":"https:\/\/regask.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","width":401,"height":401,"caption":"RegASK"},"image":{"@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","https:\/\/x.com\/ASKRegASK","https:\/\/www.linkedin.com\/company\/RegASK\/","https:\/\/www.youtube.com\/@RegASK","https:\/\/www.crunchbase.com\/organization\/regask","https:\/\/www.bloomberg.com\/profile\/company\/1691237D:SP","https:\/\/pitchbook.com\/profiles\/company\/265004-02","https:\/\/www.cbinsights.com\/company\/RegASK","https:\/\/vimeo.com\/RegASK"],"legalName":"RegASK PTE. LTD.","foundingDate":"2018","slogan":"Empowering Smarter Regulatory Decisions","description":"\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u304a\u3088\u3073\u6d88\u8cbb\u8ca1\u5411\u3051\u306e\u30a8\u30fc\u30b8\u30a7\u30f3\u30c8\u578bAI\u898f\u5236\u30a4\u30f3\u30c6\u30ea\u30b8\u30a7\u30f3\u30b9\u304a\u3088\u3073\u30ef\u30fc\u30af\u30d5\u30ed\u30fc\u30aa\u30fc\u30b1\u30b9\u30c8\u30ec\u30fc\u30b7\u30e7\u30f3\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3001RegASK\u3002RegASK\u306f\u3001\u5404\u5206\u91ce\u306b\u7279\u5316\u3057\u305fLLM\uff08\u6cd5\u898f\u5236\u7ba1\u7406\uff09\u3001\u30de\u30eb\u30c1\u30a8\u30fc\u30b8\u30a7\u30f3\u30c8AI\u30a2\u30fc\u30ad\u30c6\u30af\u30c1\u30e3\u3001\u305d\u3057\u30661,800\u540d\u3092\u8d85\u3048\u308b\u5c02\u9580\u5bb6\u304b\u3089\u306a\u308b\u30b0\u30ed\u30fc\u30d0\u30eb\u30b3\u30df\u30e5\u30cb\u30c6\u30a3\u3092\u7d44\u307f\u5408\u308f\u305b\u3001160\u30ab\u56fd\u4ee5\u4e0a\u3067\u898f\u5236\u52d5\u5411\u306e\u628a\u63e1\u3001\u5f71\u97ff\u5206\u6790\u3001\u30b3\u30f3\u30d7\u30e9\u30a4\u30a2\u30f3\u30b9\u30ef\u30fc\u30af\u30d5\u30ed\u30fc\u306e\u81ea\u52d5\u5316\u3001\u76e3\u67fb\u5bfe\u5fdc\u53ef\u80fd\u306a\u51fa\u529b\u3092\u63d0\u4f9b\u3057\u307e\u3059\u3002.","areaServed":"Worldwide","founder":{"@type":"Person","name":"Caroline Shleifer","jobTitle":"Founder & CEO"},"address":{"@type":"PostalAddress","streetAddress":"79 Science Park Drive, #06-01, Cintech IV","addressLocality":"Singapore","postalCode":"118264","addressCountry":"SG"},"contactPoint":{"@type":"ContactPoint","telephone":"+65 6817 6290","contactType":"customer service","availableLanguage":["English","French","Japanese","Spanish","Chinese","German"]},"numberOfEmployees":{"@type":"QuantitativeValue","minValue":50,"maxValue":100},"knowsAbout":["Regulatory Intelligence","Regulatory Compliance","Regulatory Affairs","Workflow Orchestration","Life Sciences Regulation","Consumer Products Regulation","AI-Driven Compliance"],"hasCertification":[{"@type":"Certification","name":"ISO\/IEC 42001:2023"},{"@type":"Certification","name":"ISO\/IEC 27001:2022"},{"@type":"Certification","name":"ISO\/IEC 27701"},{"@type":"Certification","name":"ISO\/IEC 27018:2019"},{"@type":"Certification","name":"SOC 2 Type II"}]},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926","name":"\u30ec\u30f4\u30a1\u30fb\u30a2\u30ca\u30f3\u30c0"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/ja\/wp-json\/wp\/v2\/posts\/7909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/ja\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/ja\/wp-json\/wp\/v2\/comments?post=7909"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/ja\/wp-json\/wp\/v2\/posts\/7909\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/ja\/wp-json\/wp\/v2\/media\/7926"}],"wp:attachment":[{"href":"https:\/\/regask.com\/ja\/wp-json\/wp\/v2\/media?parent=7909"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/ja\/wp-json\/wp\/v2\/categories?post=7909"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/ja\/wp-json\/wp\/v2\/tags?post=7909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}